This article is more than 5 years old. Information may no longer be current.
Allergan pharma sales increase almost 25% in second quarter
Click Here to Manage Email Alerts
Allergan posted net sales of $442 million for the second quarter of 2003. Excluding sales to its former subsidiary AMO, the company announced, it increased net sales 24.6% during the quarter compared to the same quarter 1 year ago.
For the 6 months ended June 27, Allergan reported net sales of $832.7 million, up 20.6% from the comparative period a year ago.
“Product approvals and launches continue to drive the expansion of our business model as we pursue our goal of being the premier specialty pharmaceutical company in the world,” said David Pyott, chairman of the board, president and chief executive officer of Allergan in a press release. “During the quarter, we launched two new products and received one new regulatory approval. These significant events, as well as further anticipated product approvals over the next 24 months, will help continue to drive our top and bottom lines.”
Worldwide eye care pharmaceutical sales were $253 million for the quarter, an increase of almost 23% from the year-ago figures, disallowing for currency effects, led by the company’s Botox product line, which earned $143.1 million for the quarter.
Allergan’s eye care sales were led by the Alphagan family of glaucoma management products. Alphagan P (brimonidine 0.15%) and Alphagan (brimonidine 0.2%) combined sales were $64.7 million, an increase of 8% over the same period in 2002. For the first half of 2003, sales for the Alphagan line reached $142.1 million. Worldwide net sales of Lumigan (bimatoprost) increased almost 41%, to $45 million for the quarter.
Restasis (cyclosporine ophthalmic emulsion 0.05%), for the treatment of patients with keratoconjunctivitis sicca, achieved sales of $11.8 million during the quarter. This is the drug’s first full quarter of being marketed in the United States.
Other highlights: Allergan launched anti-infective fluoroquinolone Zymar (gatifloxacin) during the quarter. Zymar is indicated for the treatment of bacterial conjunctivitis. And the company received approval from U.S. regulators for Acular LS (ketorolac) for the reduction of ocular pain and burning/stinging following corneal refractive surgery. The company plans to introduce Acular LS in the U.S. market during the third quarter.